Advertisement
News
Advertisement

Cerulean reaches two milestones with lead compound

Tue, 07/03/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Cerulean Pharma Inc. in Cambridge announced that it hit two milestones regarding trials of its lead drug candidate, CRLX101, in separate studies aimed at treating non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC).

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading